系统性红斑狼疮中低剂量糖皮质激素应停用还是继续?复发与损害累积风险的系统综述与荟萃分析
该系统综述与荟萃分析纳入17篇文献共738例停用糖皮质激素的SLE患者,评估停药后复发与损害累积风险。停药后总体复发 pooled 发生率为24%(95%CI 21,27),严重复发为13%(95%CI 8,18),停药较继续用药复发风险升高(RR 1.38, 95%CI 1.01,1.89),但严重复发风险未增加,损害指数增加风险呈边缘性降低(RR 0.64, 95%CI 0.38,1.09)。
要点
- SLE患者停用低剂量糖皮质激素后总体复发 pooled 发生率为24%,严重复发为13%。
- 停药较继续用药总体复发风险升高(RR 1.38, 95%CI 1.01,1.89),但严重复发风险未显著增加。
- 停药与SLICC/ACR损害指数增加风险呈边缘性降低相关(RR 0.64, 95%CI 0.38,1.09)。
核心结论
- 停用糖皮质激素导致SLE患者复发风险轻度增加,但严重复发风险未增加,且进一步损害风险呈边缘性降低。
研究设计与样本
- 系统综述与荟萃分析,检索PubMed、Embase、Cochrane Library和Scopus数据库自建库至2020年7月,最终纳入17篇文献共738例停用糖皮质激素的SLE患者。
主要发现
- 停药后总体复发 pooled 发生率为24%(95%CI 21,27),严重复发为13%(95%CI 8,18),复发 pooled 时间为21.08个月(95%CI 9.32,32.85)。
- 停药较继续用药复发风险升高(RR 1.38, 95%CI 1.01,1.89),但严重复发风险未增加(RR 1.77, 95%CI 0.40,7.83)。
- 停药与SLICC/ACR损害指数增加风险呈边缘性降低相关(RR 0.64, 95%CI 0.38,1.09)。
临床怎么用
- SLE患者停用低剂量糖皮质激素前应进行基线筛查以筛选合适候选患者,停药后需长期随访以可靠评估器官损害增加。
局限性
- 需基线筛查候选患者及停药后长期随访,才能可靠评估器官损害增加。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess the risk of flare and damage accrual after discontinuation of low-dose glucocorticoids (GCs) in SLE. METHODS: We performed a comprehensive literature search of the PubMed, Embase, Cochrane Library and Scopus databases from inception to July 2020 for studies concerning relapses/damage accrual in SLE patients. Pooled incidence rates of flare and time to flare with their 95% CIs after GC withdrawal were calculated. The summary risk ratio (RR) and 95% CI of flare/organ damage accrual risk were computed using a random- or fixed-effects model. RESULTS: A total of 738 SLE patients with GC discontinuation in 17 publications were eligible for the final analysis. In the primary meta-analysis, the pooled incidence of flare was 24% (95% CI 21, 27) and 13% (95% CI 8, 18) for global and major flares, respectively. Pooled time to flare was 21.08 months (95% CI 9.32, 32.85). In the secondary meta-analysis, GC discontinuation showed an increased risk of flare compared with GC continuation [RR 1.38 (95% CI 1.01, 1.89)], but the risk of major flares was not increased [RR 1.77 (95% CI 0.40, 7.83)]. Moreover, GC withdrawal was associated with a borderline risk reduction in the SLICC/ACR damage index increase compared with GC continuation [RR 0.64 (95% CI 0.38, 1.09)]. CONCLUSION: GC discontinuation leads to a slightly increased risk of flare, however, no increase in major flare and a borderline reduction of risk in further damage in SLE patients. Baseline screening for candidate patients and long-term follow-up after GC withdrawal are needed to reliably evaluate the organ damage increase.
引用
- Ji L, Xie W, Zhang Z, et al. Low-dose glucocorticoids should be withdrawn or continued in systemic lupus erythematosus? A systematic review and meta-analysis on risk of flare and damage accrual. Rheumatology (Oxford). 2021. PMID: 33576768. doi:10.1093/rheumatology/keab149
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。